Regencell Bioscience Holdings annual stock-based compensation
2021
2022
2023
2024
2025
Regencell Bioscience Holdings Stock-Based Compensation Growth & History (RGC)
Regencell Bioscience Holdings's stock-based compensation was $244,808 for fiscal 2025.
View full Regencell Bioscience Holdings company overviewRegencell Bioscience Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $244,808 | −$204,503 | −45.51% |
| 2024 | 2024-06-30 | $449,311 | −$473,312 | −51.30% |
| 2023 | 2023-06-30 | $922,623 | −$1.8M | −66.55% |
| 2022 | 2022-06-30 | $2.8M | $1.8M | +198.92% |
| 2021 | 2021-06-30 | $922,623 | — | — |
Regencell Bioscience Holdings stock-based compensation trends
Between the periods ended 2021-06-30 and 2025-06-30, Regencell Bioscience Holdings's stock-based compensation decreased from $922,623 to $244,808, a change of −$677,815.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regencell Bioscience Holdings source filings ↗